MBX Biosciences is a technology company.
MBX Biosciences has raised $155.0M across 2 funding rounds.
MBX Biosciences has raised $155.0M in total across 2 funding rounds.
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders, using its proprietary Precision Endocrine Peptide (PEP) platform to create optimized peptide hormones with extended half-life, consistent drug exposure, and less frequent dosing.[1][2][3][4] Its lead candidate, MBX 2109, a parathyroid hormone peptide prodrug, is in Phase 2 trials for chronic hypoparathyroidism; MBX 1416, a GLP-1 receptor antagonist, is in Phase 1 for post-bariatric hypoglycemia; and MBX 4291 is in IND-enabling studies for obesity and comorbidities.[1][2][3] Founded in 2018 and public since its September 2024 IPO, the company employs 43 people in Carmel, Indiana, and serves patients with underserved conditions through simplified disease management and potential best-in-class treatments.[1][4]
MBX Biosciences was founded in 2018 in Carmel, Indiana, leveraging expertise in peptide drug design from Scientific Co-Founder Richard DiMarchi, PhD, a global leader in the field.[1][3] The company emerged from the need to address limitations of native peptide therapeutics—such as short half-lives and inconsistent exposure—by pioneering the PEP platform with advanced chemical modifications for enhanced stability, potency, and pharmacokinetics.[2][3] Early traction built on this innovation, advancing a pipeline including MBX 2109 into Phase 2 trials, with CEO Peter (Kent) Hawryluk highlighting positive clinical data validating the platform's potential.[1][4]
MBX Biosciences rides the peptide therapeutics wave in biotech, capitalizing on growing demand for precision medicines in endocrine and metabolic disorders amid rising obesity, bariatric surgery complications, and rare conditions like hypoparathyroidism.[1][3][4] Timing aligns with advances in peptide engineering, enabling scalable platforms like PEP to compete with biologics while offering oral/injectable simplicity over daily supplements.[2][3] Market forces favor it: expanding GLP-1/obesity markets (e.g., via MBX 4291) and underserved niches provide tailwinds, influencing the ecosystem by validating peptide prodrugs for chronic management and potentially reducing healthcare burdens through less frequent dosing.[1][2][4]
MBX's PEP platform positions it for pipeline milestones, including Phase 2 data readouts for MBX 2109 and Phase 1 completion for MBX 1416, with MBX 4291 poised for IND filing amid obesity drug demand.[1][3] Trends like AI-accelerated peptide design and combo therapies for metabolic syndromes will shape its path, potentially expanding influence through partnerships or acquisitions in a consolidating biotech sector. As a post-IPO player with encouraging early data, MBX could deliver breakthrough change in underserved markets, transforming patient lives as its precision peptides advance.[4]
MBX Biosciences has raised $155.0M in total across 2 funding rounds.
MBX Biosciences's investors include 4BIO Capital, Access Biotechnology, Foresite Capital, Frazier Healthcare Partners, New Enterprise Associates, Northpond Ventures, OrbiMed, Takeda Ventures.
MBX Biosciences has raised $155.0M across 2 funding rounds. Most recently, it raised $120.0M Series B in November 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2022 | $120.0M Series B | 4BIO Capital, Access Biotechnology, Foresite Capital, Frazier Healthcare Partners, New Enterprise Associates, Northpond Ventures, OrbiMed, Takeda Ventures | |
| Jul 1, 2020 | $35.0M Series A | 4BIO Capital, Access Biotechnology, Foresite Capital, Frazier Healthcare Partners, New Enterprise Associates, Northpond Ventures, OrbiMed, Takeda Ventures |